Skip to content

Study · Case report or series · n = 1 · 2026

9 results

Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gaps.

Gaytan G, Pabon A, Rosario N

Journal of the American Pharmacists Association : JAPhA5 Mar 2026

PMID41794178 (opens in a new tab)DOI10.1016/j.japh.2026.103069 (opens in a new tab)PepBankPUB-41794178
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a man with an ileostomy and type 2 diabetes, semaglutide was associated with reduced appetite over 5 months.

    In plain wordsIn a man with an ileostomy, semaglutide was linked to reduced appetite.

    Peptide
    Semaglutide
    Outcome
    DecreaseAppetite
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 5 monthsAs given in this study (human).

    Source sentences

    Summary
    Initially, semaglutide was associated with reduced appetite and weight loss of 19 pounds (from 278 lbs., BMI 54.3, to 259 lbs., BMI 50.6) over 5 months.
    1 context sentence
    Summary · context
    A 56-year-old Hispanic male with type 2 diabetes, body mass index (BMI) of 54.3, and an ileostomy placed in 2012 was prescribed semaglutide for glycemic control and weight loss by an endocrinology clinic.
  2. 02HumanCase report or seriesEfficacy outcome

    In a man with an ileostomy and type 2 diabetes, semaglutide was associated with 19 pounds of weight loss over 5 months.

    In plain wordsIn a man with an ileostomy, semaglutide was linked to 19 pounds of weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 5 monthsAs given in this study (human).

    Measurements

    Weight loss
    19 pounds
    single man with ileostomy and type 2 diabetes; 5 months
    Body weight
    278 lbs.
    before semaglutide-associated weight loss
    Body weight
    259 lbs.
    after 5 months

    Source sentences

    Summary
    Initially, semaglutide was associated with reduced appetite and weight loss of 19 pounds (from 278 lbs., BMI 54.3, to 259 lbs., BMI 50.6) over 5 months.
    1 context sentence
    Summary · context
    A 56-year-old Hispanic male with type 2 diabetes, body mass index (BMI) of 54.3, and an ileostomy placed in 2012 was prescribed semaglutide for glycemic control and weight loss by an endocrinology clinic.
  3. 03HumanCase report or seriesSafety outcome

    After restarting semaglutide, a man with an ileostomy experienced progressive slowing of gastrointestinal motility.

    In plain wordsAfter restarting semaglutide, a man with an ileostomy had slower gut movement.

    Peptide
    Semaglutide
    Outcome
    DecreaseGastrointestinal motility
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Within 2 weeks of restarting, he experienced progressive slowing of gastrointestinal motility, including hard stools and bowel movements every other day.
    2 context sentences
    Summary · context
    He paused the medication 1 week prior to a scheduled colonoscopy and resumed 1 week after.
    Summary · context
    A 56-year-old Hispanic male with type 2 diabetes, body mass index (BMI) of 54.3, and an ileostomy placed in 2012 was prescribed semaglutide for glycemic control and weight loss by an endocrinology clinic.
  4. 04HumanCase report or seriesSafety outcome

    Within 2 weeks of restarting semaglutide, a man with an ileostomy experienced hard stools.

    In plain wordsWithin 2 weeks of restarting semaglutide, a man with an ileostomy had hard stools.

    Peptide
    Semaglutide
    Outcome
    Not applicableHard stools
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Within 2 weeks of restarting, he experienced progressive slowing of gastrointestinal motility, including hard stools and bowel movements every other day.
    2 context sentences
    Summary · context
    He paused the medication 1 week prior to a scheduled colonoscopy and resumed 1 week after.
    Summary · context
    A 56-year-old Hispanic male with type 2 diabetes, body mass index (BMI) of 54.3, and an ileostomy placed in 2012 was prescribed semaglutide for glycemic control and weight loss by an endocrinology clinic.
  5. 05HumanCase report or seriesSafety outcome

    After restarting semaglutide, a man with an ileostomy developed fecal impaction requiring hospitalization.

    In plain wordsAfter restarting semaglutide, a man with an ileostomy needed hospital care for fecal impaction.

    Peptide
    Semaglutide
    Outcome
    Not applicableFecal impaction requiring hospitalization
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These symptoms culminated in fecal impaction requiring hospitalization later that month.
    3 context sentences
    Summary · context
    Within 2 weeks of restarting, he experienced progressive slowing of gastrointestinal motility, including hard stools and bowel movements every other day.
    Summary · context
    He paused the medication 1 week prior to a scheduled colonoscopy and resumed 1 week after.
    Summary · context
    A 56-year-old Hispanic male with type 2 diabetes, body mass index (BMI) of 54.3, and an ileostomy placed in 2012 was prescribed semaglutide for glycemic control and weight loss by an endocrinology clinic.
  6. 06HumanCase report or seriesSafety outcome

    After fecal impaction requiring hospitalization, the patient permanently discontinued semaglutide.

    In plain wordsAfter fecal impaction, the patient permanently stopped semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicablePermanent discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    He permanently discontinued semaglutide and has not resumed since.
    3 context sentences
    Summary · context
    These symptoms culminated in fecal impaction requiring hospitalization later that month.
    Summary · context
    Within 2 weeks of restarting, he experienced progressive slowing of gastrointestinal motility, including hard stools and bowel movements every other day.
    Summary · context
    A 56-year-old Hispanic male with type 2 diabetes, body mass index (BMI) of 54.3, and an ileostomy placed in 2012 was prescribed semaglutide for glycemic control and weight loss by an endocrinology clinic.
  7. 07HumanCase report or seriesSafety outcome

    A man with an ileostomy and type 2 diabetes continued intermittent semaglutide use without complications over 18 months.

    In plain wordsA man with an ileostomy continued intermittent semaglutide use without complications over 18 months.

    Peptide
    Semaglutide
    Outcome
    Not applicableComplications during intermittent use
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    He continued intermittent use over an 18-month period without complications.
    1 context sentence
    Summary · context
    A 56-year-old Hispanic male with type 2 diabetes, body mass index (BMI) of 54.3, and an ileostomy placed in 2012 was prescribed semaglutide for glycemic control and weight loss by an endocrinology clinic.
  8. 08HumanCase report or seriesEfficacy outcome

    In a man with an ileostomy and type 2 diabetes, semaglutide was associated with BMI decreasing from 54.3 to 50.6 over 5 months.

    In plain wordsIn a man with an ileostomy, semaglutide was linked to BMI falling from 54.3 to 50.6.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody mass index
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 5 monthsAs given in this study (human).

    Measurements

    BMI
    54.3
    before semaglutide-associated change
    BMI
    50.6
    after 5 months

    Source sentences

    Summary
    Initially, semaglutide was associated with reduced appetite and weight loss of 19 pounds (from 278 lbs., BMI 54.3, to 259 lbs., BMI 50.6) over 5 months.
    1 context sentence
    Summary · context
    A 56-year-old Hispanic male with type 2 diabetes, body mass index (BMI) of 54.3, and an ileostomy placed in 2012 was prescribed semaglutide for glycemic control and weight loss by an endocrinology clinic.
  9. 09HumanCase report or seriesSafety outcome

    Within 2 weeks of restarting semaglutide, a man with an ileostomy had bowel movements every other day.

    In plain wordsWithin 2 weeks of restarting semaglutide, a man with an ileostomy had bowel movements every other day.

    Peptide
    Semaglutide
    Outcome
    Not applicableBowel movement frequency
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Within 2 weeks of restarting, he experienced progressive slowing of gastrointestinal motility, including hard stools and bowel movements every other day.
    2 context sentences
    Summary · context
    He paused the medication 1 week prior to a scheduled colonoscopy and resumed 1 week after.
    Summary · context
    A 56-year-old Hispanic male with type 2 diabetes, body mass index (BMI) of 54.3, and an ileostomy placed in 2012 was prescribed semaglutide for glycemic control and weight loss by an endocrinology clinic.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.